PET and Recovery Following Revascularization (PARR 2)

Sponsored by Ottawa Heart Institute Research Corporation

About this trial

Last updated 7 years ago

Study ID

MCT-37412

Status

Completed

Type

Interventional

Phase

Phase 3

Placebo

Accepting

18+ Years

All Sexes

Trial Timing

Ended 15 years ago

What is this trial about?

Rationale: Patients with severe ventricular dysfunction and coronary disease have high morbidity and mortality. They may benefit from revascularization, but have significant peri-operative morbidity and mortality. Positron emission tomography (PET) imaging with F-18-fluorodeoxyglucose (FDG) can detect viable myocardium that may recover from revascularization in such patients. It is unclear whether use of FDG PET in this population is improves outcome or is cost-effective. Objectives: The principal aim is to determine whether FDG PET-guided therapy is effective versus standard care. Secondary objectives are to determine whether FDG PET-guided therapy improves LV function, quality of life and is good value for money versus standard care.

What are the participation requirements?

Inclusion Criteria

* Patient is > 18 years of age.

* Documented ejection fraction of <35% attributable to CAD.

* Documented CAD

* Any patient being considered for revascularization, transplant/heart failure work up or where, in the opinion of the attending physician or surgeon, viability imaging would be considered useful in ongoing clinical management decisions.

Exclusion Criteria

* Other co-morbid conditions making survival unlikely

* < 6 weeks post myocardial infarction

* CAD unsuitable for revascularization

* emergency revascularization is required.

* severe valvular disease that requires surgery.

* Geographically inaccessible

* Lack of informed consent.